Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cingulate Inc.CING · Entity 6983 | Director | June 20, 2025 | June 24, 2025 |
| Vyant Bio, Inc.VYNT · Entity 116415 | Director · Chief Executive Officer | March 15, 2022 | March 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cingulate Inc.
Report date June 20, 2025 · Filed June 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-06-20 | Direct | 15,000 |
Reported balance
After 2025-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders.
Vyant Bio, Inc.
Report date March 15, 2022 · Filed March 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2032-03-15 | Direct | 150,000 |
Reported balance
After 2022-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 150,000 · Balance 150,000 F1: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2025 Filed Jun 24, 2025 00:02 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001641172-25-016180 · ownership.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 23:59 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001493152-24-023769 · ownership.xml · derivative · entry 3 ROBERTS JOHN A · CIK 0001249872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-12 F3 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 23:59 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 14,750 | Not disclosed Strike: $1.18 | Not disclosed |
DisclosureSEC source: 0001493152-24-023769 · ownership.xml · derivative · entry 2 ROBERTS JOHN A · CIK 0001249872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Common Stock · 14,750 shares Expires 2034-03-04 F1 · date: The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024. F4 · price: The option was issued to the reporting person in lieu of cash retainer fees of $29,500. F3 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 23:59 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001493152-24-023769 · ownership.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-03-04 F1 · date: The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024. F2 · derivative.exercise_date: The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares on the twelve-month anniversary of the date of grant. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:00 UTC | Cingulate Inc. CING · Entity 6983 | GrantStock Option (right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001493152-24-009092 · ownership.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option vests as follows: 50% on the six-month anniversary of the date of grant and the remaining shares on the twelve-month anniversary of the date of grant. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:15 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-22-007154 · ownership.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-03-15 F1 · derivative.exercise_date: The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 5,000 | $2.02 | $10,100.00 |
DisclosureSEC source: 0001493152-21-029828 · ownership.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,807 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 17:03 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 10,406 | $2.41 | $25,078.46 |
DisclosureSEC source: 0001493152-21-021244 · ownership.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,807 Read SEC document |
| May 26, 2021 Filed May 27, 2021 17:31 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 7,041 | $3.55 | $24,995.55 |
DisclosureSEC source: 0001493152-21-013101 · ownership.xml · nonDerivative · entry 2 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,117 Read SEC document |
| May 24, 2021 Filed May 27, 2021 17:31 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 7,440 | $3.38 | $25,147.20 |
DisclosureSEC source: 0001493152-21-013101 · ownership.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,076 Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 21:21 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001493152-21-007805 · ownership.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-03-30 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 16:02 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | PurchaseCommon Stock, par value $0.0001 per share | 185,436 | $0.23 | $42,650.28 |
DisclosureSEC source: 0000905718-19-000097 · ownership.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,636 Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 16:42 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | PurchaseCommon Stock, par value $0.0001 per share | 100,000 | $0.23 | $22,500.00 |
DisclosureSEC source: 0000905718-19-000053 · cancer_form4jan142019.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,200 Read SEC document |
| May 10, 2018 Filed May 14, 2018 16:08 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0000905718-18-000476 · cancergene_fm4may102018.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-05-10 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Amended and Restated Cancer Genetics, Inc. 2011 Equity Incentive Plan (the "2011 Plan"). The shares underlying the options shall become vested and exercisable over time and subject to satisfaction of certain performance conditions consistent with the Company's current business plans, provided that the optionee remains a services provider to the Company through each applicable vesting period. The exercise price is the closing price of a share of Common Stock as of the date of grant on the NASDAQ Capital Market in accordance with the terms of the 2011 Plan. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 08:19 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | PurchaseCommon Stock | 12,200 | $2.00 | $24,339.00 |
DisclosureSEC source: 0001349929-17-000098 · wf-form4_151360313084956.xml · nonDerivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,200 Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:52 UTC | Vyant Bio, Inc. CGIX · Entity 116415 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001349929-17-000017 · wf-form4_148797315614652.xml · derivative · entry 1 ROBERTS JOHN A · CIK 0001249872 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 per share · 30,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.